Novel HER2 Conjugate Promising as Salvage for Solid Tumors

A small trial of a new antibody-drug conjugate that targets HER2 produced an objective response rate of 43% in patients with HER2-positive advanced gastric cancer. The study was published in The Lancet Oncology.